Systemic lupus erythematosus disease activity index 2000

Area of Science:

• Rheumatology
• Clinical Immunology
• Systemic Lupus Erythematosus Research

Background:

• The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) is a crucial tool for assessing disease activity.
• Previous versions of SLEDAI primarily focused on new or recurrent disease manifestations.
• A need existed for an index that captures persistent disease activity for more accurate patient management.

Purpose of the Study:

• To introduce and describe the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K).
• To validate SLEDAI-2K against the original SLEDAI in predicting mortality.
• To assess SLEDAI-2K's efficacy as a measure of global disease activity in clinical settings.

Main Methods:

• Correlation analysis between SLEDAI-2K and SLEDAI using data from 960 patients.
• Validation of SLEDAI-2K's predictive power for mortality across the entire cohort.
• Inclusion of a subgroup of 212 patients with Systemic Lupus Erythematosus (SLE) for detailed clinical activity assessment by an uninvolved clinician.

Main Results:

• SLEDAI-2K demonstrated a high correlation (r = 0.97) with the original SLEDAI.
• Both SLEDAI scoring methods showed equal efficacy in predicting patient mortality (p = 0.0001).
• SLEDAI-2K and SLEDAI similarly reflected the range of disease activity as perceived by clinicians.

Conclusions:

• SLEDAI-2K effectively accounts for persistent disease activity in key lupus descriptors like rash, mucous membranes, alopecia, and proteinuria.
• The SLEDAI-2K is a validated and suitable instrument for use in clinical trials involving SLE.
• SLEDAI-2K is appropriate for prognostic studies in Systemic Lupus Erythematosus, offering a refined measure of disease activity.